Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny dose of radiation tame this skin cancer?

NCT ID NCT07310745

Disease control Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a very low dose of radiation (4 Gy) can effectively control a rare, slow-growing type of skin lymphoma called primary indolent cutaneous B-cell lymphoma. Researchers will review records from 52 patients who received this low-dose treatment to see how long the cancer stays under control and what side effects occur. The goal is to find out if lower doses can work just as well as the standard higher doses, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose radiotherapy (4 Gy)
What this could lead to
If successful, this could show that a much lower radiation dose is enough to control this rare skin lymphoma, reducing side effects while still being effective.
What could go wrong
This is a small, retrospective study (52 people), not a large controlled trial. The low dose may not work as well as standard higher doses, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

52 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study involves adult patients with early-stage (I-II) primary cutaneous indolent B-cell lymphoma (PCBCL) treated with low-dose radiotherapy (4 Gy in two sessions). Patients with a confirmed histological diagnosis of indolent B-cell lymphoma (follicular, marginal, NOS) and adequate follow-up are included. Patients with aggressive lymphomas, advanced stages, extracutaneous localisations or radiotherapy doses greater than 4 Gy are excluded.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than or equal to 18 years * Histological diagnosis of indolent B-cell lymphoma (follicular, marginal, NOS) * Primary cutaneous location * Early stage (I-II) * First diagnosis or recurrence * Low-dose radiotherapy treatment (4 Gy/2 sessions) Exclusion Criteria: * Aggressive histology lymphomas * Advanced stages * Extracutaneous localisation * Radiotherapy dose administered \> 4 Gy * Patients without histological typing * Patients without follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary cutaneous follicle center lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

indolent primary cutaneous B-cell lymphoma primary cutaneous follicle center lymphoma primary cutaneous marginal zone B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary indolent cutaneous B-cell lymphoma

Contacts and locations

Locations

  • Azienda USL IRCCS di Reggio Emilia - Sc Radioterapia

    Reggio Emilia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.